Blogs

Immune Monitor - June 2024

By SITC Communications posted 5 days ago
Be the first person to like this.
A Message from the President Over the past decade, SITC played an instrumental role in establishing immunotherapy as a pillar of cancer therapy by promoting the translation of scientific innovation into treatment solutions for patients. Given the transformative clinical impact that cancer immunotherapy has already achieved, the SITC community is confident that the next decade will bring a new generation of highly innovative and effective immunotherapy agents to the patients who need them most. We recognize that there is still much work to be done. To that end, SITC is excited to introduce our three-year strategic plan , which serves as the beacon for ...
0 comments

Melanoma CPG Update v3.1 Now Available

By SITC Scientific Publications News posted 5 days ago
1 person likes this.
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum. Rapid Update v3.1 Summary The information below provides an overview ...
0 comments

SITC Publishes First Manuscript in JITC Special Series on the Current Challenges and Opportunities in Cancer Immunotherapy

By SITC Communications posted 8 days ago
Be the first person to like this.
MILWAUKEE – A new manuscript series – The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer – outlines the current state of the immunotherapy field, elevates the most pressing challenges and proposes the promising opportunities for high clinical impact in the scientific, clinical, and regulatory arenas of cancer immunotherapy. The first manuscript of the series, “ Challenges and Opportunities in Cancer Immunotherapy: A Society for Immunotherapy of Cancer (SITC) Strategic Vision ,” is available now in the Journal for ImmunoTherapy of Cancer ( JITC ). This series updates the landmark editorial published by SITC leaders ...
0 comments

Gynecologic Cancer CPG Update v1.1 Now Available

By SITC Scientific Publications News posted 12 days ago
1 person likes this.
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum. Rapid Update v1.1 Summary The information below provides ...
0 comments

SITC Publishes First Manuscript in JITC Special Series on the Current Challenges and Opportunities in Cancer Immunotherapy

By SITC Scientific Publications News posted 12 days ago
Be the first person to like this.
On behalf of the SITC Board of Directors, we are pleased to announce the publication of a new manuscript titled, “ Challenges and Opportunities in Cancer Immunotherapy: A Society for Immunotherapy of Cancer (SITC) Strategic Vision ” available now in the Journal for ImmunoTherapy of Cancer (JITC) . This manuscript is the first in a JITC Special Series — The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer , which will outline the current state of the field, elevate the most pressing challenges, and propose the most promising opportunities for high clinical impact in the scientific, clinical, and regulatory arenas of cancer ...
0 comments

JITC Digest June 2024

By JITC Publications posted 12 days ago
Be the first person to like this.
INSIDE THIS ISSUE: Letter from the Editor | JITC Editor Picks | Cancer Immunotherapy Month TM | Popular Archive Articles Letter from the Editor Hello JITC Readers, It is with immense pleasure, humility, and gratitude that I welcome you to this month’s JITC Digest, the first in my role as Editor-in-Chief of JITC . I am honored to be at the helm of this incredible journal and look forward to working with our editors, authors, reviewers, and readers as we embrace the exciting future ahead. Firstly, I need to extend a special thank you to Dr. James Gulley for his stewardship ...
0 comments

Oncology News Burst from the FDA: FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial Carcinoma

By SITC Communications posted 14 days ago
Be the first person to like this.
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...
0 comments

June 2024 JITC Reading List: Dr. Claudia Palena

By JITC Publications posted 15 days ago
Be the first person to like this.
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC 's Basic Tumor Immunology co-Section Editor Dr. Claudia Palena . “Spatial architecture of myeloid and T cells orchestrates immune evasion and clinical outcome in lung cancer” by Katey S S Enfield et al Cancer Discov (2024) Abstract: Understanding the role of the tumor microenvironment (TME) in lung cancer is critical to improving patient outcomes. We identified four histology-independent archetype TMEs in treatment-naïve early-stage lung cancer using imaging mass cytometry in the TRACERx study (n = 81 patients/198 ...
0 comments

Oncology News Burst from the FDA: FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer

By SITC Communications posted 15 days ago
Be the first person to like this.
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...
0 comments

SITC Hosts The Current Landscape of IO Access: Increasing Access to IO Webinar

By SITC Advocacy posted 21 days ago
Be the first person to like this.
This webinar on June 5th reviewed effective strategies for cancer immunotherapy administration by providing a glance at IO access across the United States, the United Kingdom, and Nigeria. It featured presentations on different models of access, the challenges related to increasing access to immunotherapy, and explored potential solutions that can be translated into local practice and health care systems around the world. In addition, this webinar served as an opportunity for speakers and attendees to discuss the importance of guideline development, alternative strategies for ICIs, predictive biomarkers, and how these topics play a role in expanding access to ...
0 comments

Breast CPG Update v1.2 Now Available

By SITC Scientific Publications News posted 21 days ago
Be the first person to like this.
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum. Rapid Upd ate v1.2 Summary The information below ...
0 comments

Oncology News Burst from the FDA: FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma

By SITC Communications posted 25 days ago
Be the first person to like this.
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...
0 comments

ASCO 2024 Annual Meeting (June 4)

By Thomas Martin posted 27 days ago
3 people like this.
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ASCO 2024 Annual Meeting. Below is a recap of highlighted research presented from Tuesday, June 4, 2024. 2024 Scientific Highlights Safety and efficacy of immune checkpoint inhibitor atezolizumab in patients with advanced solid tumors with high tumor mutation burden LBA2509. Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial. Rafal Dziadziuszko (Department of Oncology & Radiotherapy and Early Phase Clinical Trials Centre, Medical University of ...
0 comments

SITC Publishes Collaborative Manuscript on Recommendations for Tumor Mutational Burden Assay Validation and Reporting

By SITC Scientific Publications News posted 28 days ago
Be the first person to like this.
On behalf of the Society for Immunotherapy of Cancer (SITC) and in collaboration with the Association for Molecular Pathology (AMP) and the College of American Pathologists (CAP), we are pleased to announce the publication of a new manuscript titled " Recommendations for Tumor Mutational Burden Assay Validation and Reporting: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer " in the Journal of Molecular Diagnostics . Dr. Carlo Bifulco, who serves as Chair of the SITC Pathology Committee, represented the society in this effort to ensure standardization across ...
0 comments

ASCO 2024 Annual Meeting (June 3)

By Thomas Martin posted 28 days ago
Be the first person to like this.
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ASCO 2024 Annual Meeting. Below is a recap of highlighted research presented from Monday, June 3, 2024. 2024 Scientific Highlights Combination therapy with lenvatinib and pembrolizumab is associated with clinical benefits for advanced renal cell carcinoma across a variety of biomarker subtypes 4504. Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial. Toni K. Choueiri (Dana Farber Cancer Institute, Boston, MA) reported biomarker analyses from two ...
0 comments

Breast CPG Update v1.2 Now Available

By SITC Scientific Publications News posted 29 days ago
1 person likes this.
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum. Rapid Upd ate v1.2 Summary The information below ...
0 comments

ASCO 2024 Annual Meeting (June 2)

By Thomas Martin posted 29 days ago
Be the first person to like this.
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ASCO 2024 Annual Meeting. Below is a recap of highlighted research presented from Sunday, June 2, 2024. 2024 Scientific Highlights Blockade of TIGIT improves the anti-tumor efficacy of pembrolizumab for previously treated advanced mismatch repair-deficient endometrial cancer 5502. Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study. Carlos Rojas (Bradford ...
0 comments

ASCO 2024 Annual Meeting (June 1)

By Thomas Martin posted 30 days ago
Be the first person to like this.
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ASCO 2024 Annual Meeting. Below is a recap of highlighted research presented from Saturday, June 1, 2024. 2024 Scientific Highlights Safety and efficacy of a cell-based immunotherapeutic vaccine combined with durvalumab for second-line treatment of HPV 16- or 18-positive cervical cancer 5513. An open label, single arm phase II, multicenter trial of durvalumab and BVAC-C, in patients with HPV 16- or 18-positive cervical cancer and failure of first-line platinum-based chemotherapy (DURBAC). Chel Hun ...
0 comments

ASCO 2024 Annual Meeting (May 31)

By Thomas Martin posted 06-01-2024
Be the first person to like this.
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ASCO 2024 Annual Meeting. Below is a recap of highlighted research presented from Friday, May 31, 2024. 2024 Scientific Highlights Phase I study of immune checkpoint inhibition for advanced secondary angiosarcomas 11513. Cemiplimab in locally advanced and/or metastatic secondary angiosarcomas (CEMangio): A phase II clinical trial. Stefan van Ravensteijn (Radboud UMC, Nijmegen, Gelderland, Netherlands) presented a single-arm multicenter phase II clinical trial investigating the efficacy and ...
0 comments

Gynecologic Cancer CPG Update v1.1 Now Available

By SITC Scientific Publications News posted 05-25-2024
Be the first person to like this.
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum. Rapid Update v1.1 Summary The information below provides ...
0 comments